Why the study?
Does phosphocreatinine improve clinical and hemodynamic parameters in neonates with severe posthypoxic myocardial ischemia compared to riboxine?
Cohort (n=53)
Does phosphocreatinine improve clinical and hemodynamic parameters in neonates with severe posthypoxic myocardial ischemia compared to riboxine?
Absolute Event Rate: 8.25% vs 11%
Phosphocreatinine is more effective than riboxine in improving hemodynamics and reducing mechanical ventilation time in neonates with posthypoxic myocardial ischemia.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Sinitsin et al. (2011) conducted a cohort in severe posthypoxic myocardial ischemia (n=53). Phosphocreatinine vs. Riboxine was evaluated on time of mechanical ventilation (days).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: